EVA Pharma starts exporting weekly shipments of Remdesivir-EVA Pharma® to India

Cairo, May 1, 2021 – EVA Pharma responds to the Indian government call and starts exporting COVID-19 treatment “Remdesivir-EVA Pharma®” as COVID-19 cases mount and the demand for treatments spikes.

Following an agreement with Gilead Sciences Inc, EVA Pharma’s Egypt-based factory was one of the first companies to produce Remdesivir® as a licensed manufacturer for the antiviral treatment. The agreement provides Eva Pharma with Gilead’s most updated technology as well as manufacturing specifications and methods to accelerate the timeline of the production to export to 127 countries.

So far, Remdesivir has shown significant antiviral effects in preventing the deterioration of COVID-19 mild and moderate cases while reducing the treatment period to its third in addition to lowering the need for ICU admission.

“We are keen on supplying India with any needs from Remdesivir®, intending to effectively contribute to stopping the nightmare of increasing injuries and deaths toll in the country. While our factory achieved self-sufficiency for the Egyptian need of Remdesivir®, as we are exporting to many countries from the Philippines in the east to Panama in the west, and also to Africa and Europe. And now we are working with the Indian authorities for emergency licensing approval of Remdesivir-EVA Pharma®.”